With the high in vivo delivery efficiency of chemically modified antisense oligonucleotides targeting miRNAs, trials could be conducted in GBM, which exhibits a high frequency of DNA-PKcs deficiency and has a limited standard-of-care therapeutic response and few targeted therapeutic approaches. The gene discussed is PRKDC; the disease is glioblastoma.